Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Lutathera (lutetium Lu 177 dotatate by Year
Lutathera (lutetium Lu 177 dotatate — radioligand therapy for neuroendocrine tumors GEP-NETs) ($M)
Novartis Lutathera (lutetium Lu 177 dotatate: $816M in FY2025, up 12.7% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Lutathera | 816 | 724 | 13 | 12”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lutathera (lutetium Lu 177 dotatate — radioligand therapy for neuroendocrine tumors GEP-NETs) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 816 | +12.7% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 724 | +19.7% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 605 | +28.5% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 471 | -0.8% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 475 | +6.7% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 445 | +0.9% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 441 | +164.1% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 167 | – | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up lutathera (lutetium Lu 177 dotatate
Cite this data
StockData. (2026). Novartis Lutathera (lutetium Lu 177 dotatate ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-lutathera
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.